Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 480-890-9
CAS number: 906532-68-1
Estimated oral adsorption factor 10%
Estimated respiratory adsorption factor 50%
Estimated dermal adsorption factor 10%
Low bioaccumulation potential
The hydrophilic character of Everzol Orange ED-G Crude (logPow <=
-4.0) will limit this passive diffusion and although the water
solubility is high, >= 368 g/L, the large molecular weight (816.77
g/mol) will prevent passage through the aqueous pores. Furthermore,
ionization of Everzol Orange ED-G Crude will impair the uptake since
compounds need to pass the lipid membranes in the gastrointestinal wall,
Martinez 2002. It is therefore unlikely that Everzol Orange ED-G Crude
will be absorbed to a high extent from the gastro-intestinal tract. For
risk assessment purposes the oral absorption of Everzol Orange ED-G
Crude is set at 10%. The results of the toxicity studies do not provide
reasons to deviate from this proposed oral absorption factor.
There are no data available providing direct information on
respiratory absorption. The low vapour pressure (<8.40 x 10-7 Pa)
indicates that Everzol orange ED-G crude is not available for inhalation
as a vapour. In humans, particles with aerodynamic diameters below 100
μm have the potential to be inhaled. Particles with aerodynamic
diameters below 50 μm may reach the thoracic region and those below 15
μm the alveolar region of the respiratory tract. The particle size
distribution for Everzol orange ED-G crude indicates, that the particles
of Everzol orange ED-G crude have the potential to be inhaled, with
particles present with a size <50 µm and <15 µm. Based on the particle
size distribution, particles can reach both the thoracic region as well
as the alveolar region. Based on the high water solubility, Everzol
orange ED-G crude has the potential to diffuse readily into the mucus
lining of the respiratory tract. Log Kow, molecular weight and
ionization lower the potential for absorption. For risk assessment
purposes inhalatory absorption is expected to be less than the standard
100% and is set at 50%.
A solid has to dissolve into the surface moisture of the skin
before uptake can begin. Although the water solubility for Everzol
Orange ED-G Crude is high (>= 368 g/L), the hydrophilic property (log
Pow <= - 4.0) of Everzol Orange ED-G Crude is not favourable for
penetration into the stratum corneum. According to the criteria given in
the REACH guidance R.7c, 10% dermal absorption will be considered in
case MW > 500 and log Kow <-1 and >4, otherwise 100% dermal absorption
should be used, Martinez 2002. As Everzol Orange ED-G Crude meets these
criteria for restricted dermal absorption, 10% dermal absorption is used
for risk assessment purposes.
Base on the physic-chemical properties of Everzol Orange ED-G
crude, the potential for bioaccumulation is considered to be low.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
Do not show this message again